About The ASCO Post
Rights and Permissions
In the Clinic
View By Issue
2018 ASCO Annual Meeting
23rd Congress of EHA
AACR Annual Meeting 2018
Methotrexate–Induced Kidney Injury
The Policy, Politics
Today In Oncology
EHA 2018: Elotuzumab Plus Pomalidomide and Low-Dose Dexamethasone vs Pomalidomide/Dexamethasone Alone in Relapsed or Refractory Multiple Myeloma
EHA 2018: Obinutuzumab or Rituximab Plus Chlorambucil in CLL
EHA 2018: Alvocidib in Patients With Relapsed or Refractory MCL-1–Dependent AML
Final Overall Survival Analysis of First-Line Crizotinib vs Chemotherapy in Advanced
EHA 2018: Tisagenlecleucel Demonstrates More Than 1-Year Durability of Response in Adults With Relapsed or Refractory DLBCL
Most Read Stories
Abiraterone or Docetaxel: Which Is Optimal for Hormone-Sensitive High-Risk Prostate Cancer?
Eating a High-Quality Diet Could Decrease Cancer Survivors’ Risk of Death by 65%
Is CAR T-Cell Therapy Setting a New Standard of Care in Lymphoma?
2018 ASCO: KEYNOTE-042 Trial Compares Pembrolizumab With Chemotherapy as First-Line Treatment of NSCLC With PD-L1 Expression of 1% or More
FDA Approves Pembrolizumab for Previously Treated Recurrent or Metastatic PD-L1–Expressing Cervical Cancer
© 2018 HSP News Service, L.L.C.
to learn more.